PDCD1 and neoplasm: Currently, immune checkpoint molecules of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death receptor (PD-1), as the most promising tumor immunotherapies, have received more attention in clinical applications [9, 10].